KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $961.0 million.

  • Amgen's Free Cash Flow fell 7815.91% to $961.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.1 billion, marking a year-over-year decrease of 2207.04%. This contributed to the annual value of $8.1 billion for FY2025, which is 2207.04% down from last year.
  • Latest data reveals that Amgen reported Free Cash Flow of $961.0 million as of Q4 2025, which was down 7815.91% from $4.2 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Free Cash Flow ranged from a high of $4.4 billion in Q4 2024 and a low of $289.0 million during Q4 2023
  • Moreover, its 5-year median value for Free Cash Flow was $2.1 billion (2021), whereas its average is $2.2 billion.
  • As far as peak fluctuations go, Amgen's Free Cash Flow tumbled by 8748.38% in 2023, and later soared by 142249.13% in 2024.
  • Quarter analysis of 5 years shows Amgen's Free Cash Flow stood at $2.5 billion in 2021, then dropped by 8.41% to $2.3 billion in 2022, then crashed by 87.48% to $289.0 million in 2023, then surged by 1422.49% to $4.4 billion in 2024, then tumbled by 78.16% to $961.0 million in 2025.
  • Its last three reported values are $961.0 million in Q4 2025, $4.2 billion for Q3 2025, and $1.9 billion during Q2 2025.